Medix Biochemica's PROM (premature rupture of foetal membranes) test:
This article was originally published in Clinica
Executive Summary
Medix Biochemica's Actim PROM test is designed to rapidly detect the premature rupture of foetal membranes (PROM). The test has been marketed outside the US since 1995, and it was the first commercial test to recognise a protein highly specific for amniotic fluid, claimed the Kauniainen, Finland-based firm. This makes it less susceptible to common interfering factors that cause possible false positive or false negative results in other test methods, the company said. Last year, the firm won the first round in its legal wrangle with US company N-Dia concerning the infringement of patents related to diagnostic methods and test kits for detecting PROM (see Clinica No 1208 p 13).
You may also be interested in...
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.